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NUCLEIC ACID ENCODING HUMAN REV1 
PROTEIN 
RELATED APPLICATIONS 
This application claims priority from Us. Provisional 
Application Serial No. 60/162,140, ?led Oct. 29, 1999, 
incorporated herein by reference. 
FIELD OF THE INVENTION 
The present invention relates to the cloning and expres 
sion of a human gene encoding a protein having deoxycyti 
dyl (dCMP) transferase activity. The present invention also 
provides methods for expressing the gene, and cancer treat 
ing methods using inhibitors to the gene. 
BACKGROUND OF THE INVENTION 
DNA damage can lead to mutations during replication. In 
the yeast S. cerevisiae, it appears that the majority of 
induced mutations are generated through the damage 
induced mutagenesis pathWay (1,2). The required yeast 
genes in this pathWay include: RAD6, RAD18, REV1, 
REV3, REV6, REV7, and NGM2 (1—7), most of Which have 
been isolated by gene cloning. As expected, inactivating 
these mutagenesis genes dramatically decreases the muta 
tion frequency folloWing DNA damage (3,8). 
Rad6 is a ubiquitin-conjugating enZyme (9) and forms a 
complex With Rad18 (10—12). It has been proposed that this 
complex may play an important role in the initial steps of the 
damage-induced mutagenesis pathWay (10). Rev3 protein is 
a DNA polymerase (DNA polymerase <Q) capable of trans 
lesion DNA synthesis (13). In contrast to the replicative 
DNA polymerases, deletion of the yeast REV3 gene does not 
lead to lethality Hence, this polymerase is speci?cally 
required for damage-induced mutagenesis in yeast. Rev1 
belongs to the UmuC family of proteins (14). It possesses a 
deoxycytidyl (dCMP) transferase activity in a template 
dependent reaction, Which can ef?ciently insert a dCMP 
opposite a template AP (apurinic/apyrimidinic) site (15). 
Yeast Rad30, an E. coli DinB homologue, is another member 
of the UmuC family (14,16,17). HoWever, unlike Rev1, 
Rad30 is not a component of the damage-induced mutagen 
esis pathWay, but appears to be involved in a novel error-free 
lesion bypass mechanism (16,17). Most recently, Rad30 Was 
shoWn to be a nonessential DNA polymerase (pol 11) capable 
of error-free translesion DNA synthesis opposite a TT dimer 
in vitro (18). Apparently, the UmuC family of proteins are 
involved in different mechanisms in the damage tolerance 
response to unrepaired DNA lesions during replication. 
It is only very recently that the damage-induced mutagen 
esis pathWay in humans has been investigated. TWo human 
homologues of the yeast RAD6 gene have been identi?ed: 
HHR6A and HHR6B (19,20). Additionally, hREV3 has been 
isolated as the human homologue of the yeast mutagenic 
DNA polymerase Q (21,22). Thus, it is most likely that a 
damage-induced mutagenesis pathWay similar to that in 
yeast is operational in humans. Given the genetic complex 
ity of the yeast mutagenesis pathWay, it is certain that more 
human mutagenesis genes remain to be identi?ed. Since 
mutations are the building blocks of human cancers, under 
standing the damage-induced mutagenesis pathWay in 
humans is a key to the understanding of carcinogenesis. 
Isolating the human mutagenesis genes and elucidating the 
activities of these gene products are essential steps in these 
studies. 
There is alWays a need for more effectively diagnosing, 
preventing and treating cancer. This applies to the determi 
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nation of polypeptides that are involved in causing muta 
tions that lead to the formation of tumors and further 
mutations that cause metastasis to occur. 
SUMMARY OF THE INVENTION 
Applicants have isolated a full-length cDNA representing 
the homologue of the yeast Rev1 mutagenesis protein. 
Applicants also determined the chromosomal location of the 
human REV1 gene and demonstrated its ubiquitous expres 
sion in various human tissues. Furthermore, Applicants have 
demonstrated that the human REV1 protein is a dCMP 
transferase capable of inserting a dCMP opposite a template 
AP site. 
The present invention also relates to antibodies, including 
monoclonal or polyclonal antibodies, and antibody frag 
ments that have speci?c interaction With epitopes present on 
hREV1. The present invention is also directed to methods of 
preventing, treating, or ameliorating a disease condition or 
disorder in an individual comprising the step of administer 
ing a therapeutically effective amount of hREV1 protein or 
its inhibitor or activator to the individual. The present 
invention is also directed to methods or protocols in treat 
ment or prevention of a disease or disorder based on the gene 
and gene product described in the present application. 
The present invention is related to an isolated nucleic acid 
molecule that encodes: 
a polynucleotide Which encodes the polypeptide set forth 
in Table 1; 
a polynucleotide Which encodes a variant of the polypep 
tide set forth in Table 1 Wherein said variant has a 
deoxycytidyl transferase activity; 
a polynucleotide Which encodes a homologous variant of 
said polypeptide set forth in Table 1 having less than 
about 750 amino acid changes; or 
a polynucleotide sequence Which hybridiZes to the poly 
nucleotide of Table 1 under the folloWing conditions: 
prehybridiZe the membrane in solution of 0.25M 
sodium phosphate, 0.25 M NaCl, 1 mM EDTA, 
5%SDS and 50% formamide for 1 to 4 hours at 42° 
C. and then hybridiZe in the same solution With 
denatured labeled DNA probe and at 42° C. for 
overnight. After hybridiZation, Wash the membrane 
With 0.2><SSPE, 0.1% SDS at 42° C. for 30 minutes 
and then Wash in more stringent condition With 
0.1><SSPE, 0.05%SDS at higher temperature, for 
example, at 55° C. for 30 minutes. Preferably, the 
polynucleotide is a DNA. More preferably, the DNA 
comprises a DNA encoding the polypeptide 
sequence of Table 1. 
The present invention is further directed to a vector, 
comprising: 
a replicable vector; and 
the above-describe polynucleotide inserted into said vec 
tor. 
The present invention is also directed to polypeptides 
encoded by the nucleic acid described above. 
The present invention is related to a pharmaceutical 
composition comprising: 
a therapeutically effective amount of an inhibitor to the 
above described polypeptide; and 
a pharmaceutically acceptable carrier or diluent. 
It is an object of the invention to provide a method of 
preventing tumor formation, comprising administering to a 
person in need thereof, a prophylactic amount of an inhibitor 
to human deoxycytidyl transferase. Preferably, the inhibitor 
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blocks transcription or translation of the deoXycytidyl trans 
ferase gene. Also preferred is that the inhibitor blocks 
activity of the deoXycytidyl transferase protein by binding to 
the protein, in Which case the preferred inhibitor is an 
antibody, more preferably, a monoclonal antibody. 
Another object of the invention is to provide a method for 
treating or sloWing metastasis of a tumor, comprising admin 
istering to a person in need thereof, a therapeutically effec 
tive amount of an inhibitor to human deoXycytidyl trans 
ferase. 
Yet another object of the present invention is to provide a 
method for preventing mutations in a person, comprising 
administering to a person in need thereof, a therapeutically 
effective amount of an inhibitor to human deoXycytidyl 
transferase. 
Table 1 describes the nucleotide and the deduced amino 
acid sequences of the human REV1 (hREV1) gene. Nucle 
otide sequence of the full-length hREV1 is shoWn in upper 
case letters While the 5‘ and the 3‘ nontranslated regions are 
shoWn in loWer case letters. The deduced amino acid 
sequence is shoWn by the single letter symbols of amino 
acids. A mini open reading frame upstream of the hREV1 
open reading frame is shoWn by the underline. The bold-type 
indicates the putative polyadenylation signal. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The present invention Will become more fully understood 
from the detailed description given hereinbeloW, and the 
accompanying draWings Which are given by Way of illus 
tration only, and thus are not limitative of the present 
invention, and Wherein; 
FIG. 1.—Northern blot analysis of the human REV1 
mRNA. A RNA sample prepared from normal human heart 
tissue Was separated by electrophoresis and hybridiZed With 
a 32P-labeled 59-mer oligonucleotide probe speci?c to the 
human REV1, as described in Materials and Methods. The 
hybridiZed human REV1 mRNA Was visualiZed by autora 
diography. The RNA siZe markers in kilobase are indicated 
on the right. 
FIG. 2.—Conservation betWeen the yeast and the human 
REV1 proteins. The yeast and the human REV1 protein 
sequences Were aligned, and the signi?cantly conserved 
regions of the proteins are schematically indicated by simi 
larly shaded areas. The yeast Rev1 is shoWn at the top and 
the human REV1 at the bottom. The amino acid sequence 
identity and similarity Within each conserved region are 
indicated. 
FIG. 3.—Conserved structural domain and sequence 
motifs of REV1 proteins from various biological sources. 
Several sequence features Were identi?ed by aligning REV1 
protein sequences of various organisms as indicated. Iden 
tical amino acid residues are shaded. Similar amino acid 
residues are shoWn as “+” in the consensus sequence. 
Numbers in parentheses indicate gaps in the alignment. 
BRCT domain, the BRCA1 C-terminus domain; I—V, REV1 
protein sequence motifs I to V. The REV1 sources are: ce, C. 
elegans (GenBank accession number Z46812); at, A. 
thaliana (GenBank accession number AC002342); sc, S. 
cerevisiae (GenBank accession number M22222); sp, S. 
pombe (GenBank accession number AL035548); h, H. Sapi 
ens (GenBank accession number AF 151538). 
ceRev1 BRCT domain is SEQ ID NO:10 
ceRev1 sequence motif I is SEQ ID NO:11 
ceRev1 sequence motif II is SEQ ID NO:12 
ceRev1 sequence motif III is SEQ ID NO:13 
ceRev1 sequence motif IV is SEQ ID NO:14 
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ceRev1 sequence motif V is SEQ ID NO:15 
atRev1 BRCT domain is SEQ ID NO:16 
atRev1 sequence motif I is SEQ ID NO:17 
atRev1 sequence motif II is SEQ ID NO:18 
atRev1 sequence motif III is SEQ ID NO:19 
atRev1 sequence motif IV is SEQ ID NO:20 
atRev1 sequence motif V is SEQ ID NO:21 
scRev1 BRCT domain is SEQ ID NO:22 
scRev1 sequence motif I is SEQ ID NO:23 
scRev1 sequence motif II is SEQ ID NO:24 
scRev1 sequence motif III is SEQ ID NO:25 
scRev1 sequence motif IV is SEQ ID NO:26 
scRev1 sequence motif V is SEQ ID NO:27 
spRev1 BRCT domain is SEQ ID NO:28 
spRev1 sequence motif I is SEQ ID NO:29 
spRev1 sequence motif II is SEQ ID NO:30 
spRev1 sequence motif III is SEQ ID NO:31 
spRev1 sequence motif IV is SEQ ID NO:32 
spRev1 sequence motif V is SEQ ID NO:33 
hRev1 BRCT domain is SEQ ID NO:34 
hREV1 sequence motif I is SEQ ID NO:35 
hREV1 sequence motif II is SEQ ID NO:36 
hREV1 sequence motif III is SEQ ID NO:37 
hREV1 sequence motif IV is SEQ ID NO:38 
hREV1 sequence motif V is SEQ ID NO:39 
FIG. 4.—EXpression of the REV1 gene in various human 
tissues. First strand cDNA Was synthesiZed from polyA+ 
mRNA of various human tissues as indicated and normal 
iZed against the constitutive gene glyceraldehyde-3 
phosphate dehydrogenase. A 360-bp DNA fragment 
corresponding to position +773 to +1132 of the human 
REV1 cDNA Was ampli?ed by 35 cycles of PCR as 
described in Materials and Methods. DNA products Were 
separated by electrophoresis on a 1% agarose gel and 
visualiZed by ethidium bromide staining. The siZe markers 
in bp are shoWn on the right. 
FIG. 5.—The dCMP transferase activity of the human 
REV1 protein. A. The DNA substrate used for dCMP 
transferase assays. The 18-mer primer Was labeled With 32P 
at its 5‘ end. B. Standard dCMP transferase assays Were 
performed in the reaction buffer containing a single dNTP 
(A, C, G, or T, lanes 1—8) or all four dNTPs (N4, lanes 9 and 
10) as described in Material and Methods. Protein samples 
used Were 2 pl of the partially puri?ed human REV1 (lanes 
2, 4, 6, 8, and 10), or 2 pl of an identically puri?ed protein 
fraction from the rev1 deletion mutant cells (lanes 1, 3, 5, 7, 
and 9). DNA siZe markers in nucleotides are indicated on the 
right. 
FIG. 6.—Transferase activity of the human REV1 protein 
opposite a template AP site. A. The DNA substrates used for 
dCMP transferase assays. The X position is a U Without 
uracil-DNA glycosylase (UDG) treatment, or anAP site With 
UDG treatment. The 17-mer primer Was labeled With 32P at 
its 5‘ end. B. Complete conversion of uracil-containing 
templates into AP site-containing templates. After convert 
ing the site-speci?c uracil residue into an AP site by UDG 
treatment (UDG, +), the template (0.4 pmol) Was incubated 
With 500 ng of E. coli endonuclease III at 37° C. for 30 min 
(Endo III, +). Endo III cleaves DNA strand speci?cally at the 
AP site. The reaction products Were separated by electro 
phoresis on a 15% native polyacrylamide gel and visualiZed 
by autoradiograpgy. Lanes 1 and 3 are controls Without any 
treatment or With Endo III treatment only, respectively. C. 
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Standard dCMP transferase assays Were performed With 2 pl 
of the partially puri?ed human REV1 in the reaction buffer 
containing a single dNTP (A, C, G, or T, lanes 1—8) or all 
four dNTPs (N4, lanes 9 and 10) as described in Material 
and Methods. +UDG, AP site template; —UDG, uracil 
containing template. Lanes 11 and 12, control experiments 
Without dNTPs in the reaction mixtures. DNA siZe markers 
in nucleotides are indicated on the right. 
FIG. 7.—Pure human REV1 protein and its transferase 
activity. To con?rm that the dCMP transferase activity is 
intrinsic to the human REV1, the protein Was puri?ed to 
apparent homogeneity as described in Materials and Meth 
ods. A. The most pure Mono Q fraction Was separated by 
electrophoresis on a 10% SDS-polyacrylamide gel using 10 
pl of the sample. The His-tagged human REV1 protein Was 
visualiZed by silver staining. Protein siZe markers (lane M) 
in kDa are indicated on the left. B. The identity of the human 
REV1 protein Was con?rmed by Western blot using a 
monoclonal antibody against the His tag. C. A transferase 
assay Was performed using the AP site-containing template 
(see FIG. 6A) Without (lane 1) or With (lane 2) the pure 
human REV1 protein (2 pl, ~10 ng) in a reaction volume of 
5 pl at 30° C. for 30 min. The reaction products Were 
separated by electrophoresis on a 12% sequencing gel and 
visualiZed by autoradiography. DNA siZe markers in nucle 
otides are indicated on the right. 
DETAILED DESCRIPTION OF THE 
INVENTION 
DNA damage-induced mutagenesis is an important cel 
lular response to unrepaired DNA lesions during replication. 
The biological outcome of this pathWay is enhanced cell 
survival and increased mutations folloWing DNA damage. 
The yeast S. cerevisiae has served as the most informative 
model organism in the studies of the damage-induced 
mutagenesis pathWay in eukaryotes. Yeast genetic analyses 
have implicated at least 7 genes in this mutagenesis pathWay, 
including REV1 (27). 
Applicants have isolated a full-length cDNA of the yeast 
REV1 counterpart in humans. The REV1 protein is con 
served from yeast to humans. Some regions share over 30% 
identity and more than 50% similarity betWeen the yeast and 
the human proteins. The REV1 protein is additionally found 
in S. pombe, C. elegans, and A. thaliana, With signi?cant 
sequence homologies among them. REV1 proteins of vari 
ous sources all contain an N-terminal BRCT domain. It Was 
originally identi?ed in the breast cancer suppressor protein 
BRCA1 and subsequently found in some other proteins 
involved in cell cycle checkpoints, DNA repair, and 
recombination, such as Rad9, p53-binding protein, XRCC1, 
and DNA ligases III and IV (28—30). This structural domain 
is important in protein-protein interactions (31). Thus, it is 
likely that REV1 may interact With other proteins during 
damage-induced mutagenesis, although none of the REV1 
interactions have been identi?ed. Additionally, REV1 pro 
teins contain several conserved sequence motifs (I—V), 
Which closely resemble those of E. coli UmuC-related 
proteins (14). 
Examination of the 5‘ untranslated region of the human 
REV1 cDNA revealed the presence of an out-of-frame AT G 
at nucleotide position —35 Which initiates an ORF of 12 
codons and terminates at position +2. The stop codon of this 
mini-ORE overlaps With the human REV1 initiator AT G 
codon. The sequence context of this upstream ATG is close 
to the consensus KoZak sequence (26). Thus, it is likely that 
the translational ef?ciency of the human REV1 message 
may be reduced by the presence of this upstream mini ORF. 
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Structural features of the human REV3 gene also suggest a 
loW-level expression (21,22). These features imply that 
under normal groWth conditions human cells may contain 
limited amounts of the mutagenesis proteins. 
Most recently, by employing the yeast tWo-hybrid system 
Wixlerr et al. (32) identi?ed a partial human cDNA Whose 
polypeptide interacts With the cytoplasmic domain of the 
ot3A integrin subunit. This cDNA clone (alpha integrin 
interacting protein 80, AIBP80) corresponds to the 2.6 kb of 
the 3‘ end of our human REV1 cDNA, With a feW sequence 
discrepancies. This sequence Was localiZed by the Sanger 
Centre betWeen 2q11.1 and 2q11.2, a region identical to 
Applicants’ human REV1 chromosomal location. 
Applicants found that the human REV1 protein is a dCMP 
transferase capable of inserting a dCMP opposite a template 
AP site. This activity provides evidence supporting a role of 
the REV1 protein in damage-induced mutagenesis in 
humans. In vitro, the human REV1 dCMP transferase func 
tions ef?ciently opposite a template AP site. Thus, the human 
REV1 transferase may play a critical role during mutagenic 
translesion DNA synthesis opposite a template AP site in 
vivo. Supporting this notion, Johnson et al. (33) recently 
demonstrated that AP site-induced mutagenesis in yeast 
requires the Rev1 protein. The results presented herein also 
suggest that the damage-induced mutagenesis pathWay Will 
incorporate a C residue opposite an AP site during human 
DNA replication, regardless of the original base identity 
previously residing at the AP site. Since REV1 is also 
needed for UV-induced mutagenesis in yeast (27), additional 
function of the protein must be involved during mutagenesis 
opposite other DNA lesions. 
Yeast Rev1 is also a dCMP transferase (15). Thus, detec 
tion of the dCMP transferase activity of the human REV1 
indicates that it is both a structural and a functional homo 
logue of the yeast protein. Additionally, humans contain 
highly conserved homologues of the yeast mutagenesis 
proteins Rad6 (19,20) and Rev3 (21,22). Taken together, 
these observations clearly indicate the existence of a 
damage-induced mutagenesis pathWay in humans in 
response to DNA lesions. Further supporting this 
conclusion, Gibbs et al (21) shoWed that UV-induced 
mutagenesis in human cells requires the human REV3. The 
damage-induced mutagenesis pathWay is likely a fundamen 
tal and major mechanism for generating mutations in 
humans after DNA damage. Consistent With this hypothesis, 
ubiquitous expression for both REV1 and REV3 (22) in 
various human tissues Was observed. 
Abbreviations 
Abbreviations for amino acids used herein are conven 
tionally de?ned as described hereinbeloW unless otherWise 
indicated. 
Three-letter One-letter 
Amino Acid abbreviation symbol 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Asparagine or aspartic acid Asx B 
Cysteine Cys C 
Diaminopropionic acid Dpr 
Glutamine Gln Q 
Glutamic acid Glu E 
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-continued 
Three-letter One-letter 
Amino Acid abbreviation symbol 
Glutamine or glutamic acid Glx Z 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Ornithine Orn 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
Speci?cally Exempli?ed Polypeptides 
The present invention relates to polypeptides comprising 
the sequences exempli?ed in Table 1. The polypeptide can 
be prepared by isolation from natural sources, polypeptide 
synthesis by knoWn synthetic methods, or expression and 
recovery from a recombinant organism or by any other 
convenient method. 
Variants of Polypeptide 
Variants of the speci?cally exempli?ed polypeptides are 
also encompassed by the present invention. Possible variants 
include allelic variants and corresponding polypeptides from 
other organisms, particularly other organisms of the same 
species, genus or family. The variants may have substan 
tially the same characteristics as the natural polypeptides. 
The variant polypeptide Will possess one or more or all of 
the folloWing physical and/or biological properties. Physical 
properties: ~140 kDa as determined by electrophoresis on a 
10% SDS-polyacrylamide gel. Biological properties: deoxy 
cytidyl transferase activity of the polypeptide that catalyzes 
the insertion of a dCMP to a DNA primer opposite a 
template G residue or a template apurinic/apyrimidinic site as dete mined by a primer extension assay. 
Primer extension assay: a DNA template or a DNA 
oligonucleotide annealed With a 32P-labeled DNA primer 
right before the template G residue or the template AP site. 
Incubation of this DNA substrate With the polypeptide 
containing a dCMP transferase activity under a standard 
DNApolymerase assay buffer Will extend the labeled primer 
one nucleotide longer Which is detected by a sequencing gel. 
Inactivation or inhibiting this polypeptide through chemical, 
biochemical, or molecular techniques Will lead to inhibition 
of mutagenesis induced by ultraviolet (UV) and possibly 
some other DNA damaging agents. Mutagenesis is deter 
mined by a standard mutation assay in human cells such as 
the HPRT forWard mutation assay measuring mutations that 
confer cells resistance to 6-thioguanine (Quan, T., Reiners, 
J. J., Jr., Culp, S. J., Richter, P., and States, J. C. (1995) M01. 
Carcinog. 12, 91—102). 
Substitutions, Additions and Deletions 
As possible variants of the above speci?cally exempli?ed 
polypeptides, the polypeptide may have additional indi 
vidual amino acids or amino acid sequences inserted into the 
polypeptide in the middle thereof and/or at the N-terminal 
and/or C-terminal ends thereof so long as the polypeptide 
possesses the desired physical and/or biological character 
istics. Likewise, some of the amino acids or amino acid 
sequences may be deleted from the polypeptide so long as 
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the polypeptide possesses the desired physical characteris 
tics. Amino acid substitutions may also be made in the 
sequences so long as the polypeptide possesses the desired 
physical and biochemical characteristics. 
Sequence Identity at the Amino Acid Level 
The variants of polypeptides contemplated herein should 
possess more than 75% sequence identity (sometimes 
referred to as homology, preferably more than 85% identity, 
most preferably more than 95% identity, even more prefer 
ably more than 98% identity to the naturally occurring 
and/or speci?cally exempli?ed polypeptides or fragments 
thereof described herein. To determine this homology, tWo 
polypeptides are aligned so as to obtain a maximum match 
using gaps and inserts. 
TWo sequences are said to be “identical” if the sequence 
of residues is the same When aligned for maximum corre 
spondence as described beloW. The term “complementary” 
applies to nucleic acid sequences and is used herein to mean 
that the sequence is complementary to all or a portion of a 
reference polynucleotide sequence. 
Optimal alignment of sequences for comparison can be 
conducted by the local homology algorithm of Smith and 
Waterman,Aa'd. Appl. Math, 2:482 (1981), by the homology 
alignment method of Needleman and Wunsch, J. M01. Bi0l., 
48:443 (1970), by the search for similarity method of 
Pearson and Lippman, Proc. Natl. Acad. Sci. USA, 85 :2444 
(1988), or the like. Computer implementations of the above 
algorithms are knoWn as part of the Genetics Computer 
Group (GCG) Wisconsin Genetics Software Package (GAP, 
BESTFIT, BLASTA, FASTA and TFASTA), 575 Science 
Drive, Madison, Wis. 
“Percentage of sequence identity” is determined by com 
paring tWo optimally aligned sequences over a comparison 
WindoW, Wherein the portion of the sequence in the com 
parison WindoW may comprise additions or deletions (i.e. 
“gaps”) as compared to the reference sequence for optimal 
alignment of the tWo sequences being compared. The per 
centage identity is calculated by determining the number of 
positions at Which the identical residue occurs in both 
sequences to yield the number of matched positions, divid 
ing the number of matched positions by the total number of 
positions in the WindoW and multiplying the result by 100 to 
yield the percentage of sequence identity. Total identity is 
then determined as the average identity over all of the 
WindoWs that cover the complete query sequence. 
Post-translational Modi?cation 
Also included Within the scope of the present invention 
are polypeptides or fragments or derivatives thereof Which 
are differentially modi?ed during or after translation, e. g., by 
glycosylation, proteolytic cleavage, phosphorylation, 
methylation, and amidation of glutamic acid, aspartic acid 
and C-terminal carboxyl groups, lipid modi?cation, such as 
prenylation and palmitoylation, and acetylation of the 
N-terminus. 
Fusion Polypeptides 
The polypeptide of the present invention may be 
expressed as a fusion polypeptide or chimeric polypeptide 
With a second polypeptide. The second polypeptide Will 
usually impart an additional property or characteristic to the 
fusion polypeptide Which is not possessed by the polypep 
tide of the present invention. 
Fragments of Polypeptide 
Fragments of the full length polypeptides such as pro 
teolytic cleavage fragments Which contain at least one, and 
preferably all, of the above-listed physical and/or biological 
properties are also encompassed by the present invention. 
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The polypeptide or fragment or variant thereof usually has 
a length of at least about 100 amino acids, usually less than 
1,300 amino acids, preferably betWeen 500 and 1,300 amino 
acids, more preferably betWeen 500 and 900 amino acids. 
Signi?cantly featured regions: the BRCT domain from 
amino acid 48 to amino acid 140 of the human REV1 protein 
may be involved in interactions With other proteins. 
REV1 motif I from amino acid 344 to amino acid 380 of 
the human REV1 protein may be involved in the catalytic 
activity of the REV1 protein. 
REV1 motif II from amino acid 415 to amino acid 450 of 
the human REV1 protein may be involved in the catalytic 
activity of the REV1 protein. 
REV1 motif III from amino acid 523 to amino acid 570 
of the human REV1 protein may be involved in the catalytic 
activity of the REV1 protein. 
REV1 motif IV From amino acid 580 to amino acid 620 
of the human REV1 protein may be involved in the catalytic 
activity of the REV1 protein. 
REV1 motif V from amino acid 621 to amino acid 662 of 
the human REV1 protein may be involved in the catalytic 
activity of the REV1 protein. All of these regions are shoWn 
in FIG. 3. 
Production of Recombinant Polypeptide 
The present invention is also directed to a neW polypep 
tide and a method for producing the polypeptide. The 
recombinant polypeptide should possess one or more of the 
above-described biological and/or physical properties. 
Recombinant polypeptide can be produced by a process 
Which comprises culturing the transformed cell or microor 
ganism described herein under conditions Which alloW 
expression of the polypeptide, optionally recovering the thus 
expressed polypeptide and optionally purifying the recov 
ered polypeptide. In the processes for the synthesis of the 
polypeptide, DNA Which encodes the polypeptide is ligated 
into a replicable (reproducible) vector, the vector is used to 
transform host cells, and the polypeptide is recovered from 
the culture. Suitable replicable vectors Will be selected 
depending upon the particular host cell chosen. Suitable 
processes are knoWn in the art and are described, for 
example, in Sambrook et al, Molecular Cloning: A Labora 
tory Manual, 2nd Ed. c. 1989 by Cold Spring Harbor 
Laboratory Press, Cold Spring Harbor, NY, Chapters 16, 17 
and 18. 
The polypeptide produced in this manner may be different 
from natural polypeptide in that it may be free of other 
polypeptides or materials Which occur in natural polypep 
tide. The polypeptide produced by recombinant techniques 
may also contain some small amounts of contaminating 
materials from the microorganism, cells and/or fermentation 
system in Which it Was produced. Thus, the present invention 
is also directed to these neW or isolated polypeptides Which 
are produced by recombinant DNA techniques. 
Puri?cation of Recombinant Polypeptide 
Recombinant polypeptide can be recovered from cultures 
by lysing the cells to release recombinant polypeptide Which 
is present inside the cells. Initially, cell debris can be 
separated by centrifugation. The remaining debris and the 
supernatant are then repeatedly treated With solvents in 
Which the cell debris are soluble but in Which the recombi 
nant polypeptide is not soluble to thereby precipitate recom 
binant polypeptide. These procedures can be repeated and 
combined With other procedures including ?ltration, dialysis 
and/or chromatography to obtain a pure product. 
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DNA and RNA 
The invention encompasses DNA that codes for any one 
of the above-described polypeptides including, but not lim 
ited to, those shoWn in Table 1, including fusion 
polypeptides, variants and fragments thereof. The sequence 
of the cDNA Which has actually been sequenced is shoWn in 
Table 1. The present invention also includes cDNA as Well 
as genomic DNA containing or comprising the requisite 
nucleotide sequences as Well as corresponding RNA and 
antisense sequences. 
Cloned DNA Within the scope of the invention also 
includes allelic variants of the speci?c sequences presented 
in Table 1. An “allelic variant” is a sequence that is a variant 
from that of the exempli?ed nucleotide sequence, but rep 
resents the same chromosomal locus in the organism. In 
addition to those Which occur by normal genetic variation in 
a population and perhaps ?xed in the population by standard 
breeding methods, allelic variants can be produced by 
genetic engineering methods. A preferred allelic variant is 
one that is found in a naturally occurring organism, includ 
ing a laboratory strain. Allelic variants are either silent or 
expressed. A silent allele is one that does not affect the 
phenotype of the organism. An expressed allele results in a 
detectable change in the phenotype of the trait represented 
by the locus. 
A nucleic acid sequence “encodes” or “codes for” a 
polypeptide if it directs the expression of the polypeptide 
referred to. The nucleic acid can be DNA or RNA. Unless 
otherWise speci?ed, a nucleic acid sequence that encodes a 
polypeptide includes both the transcribed strand and the 
mRNA or the DNA representative of the mRNA. An “anti 
sense” nucleic acid is one that is complementary to a strand 
representative of mRNA, including untranslated portions 
thereof. 
Degenerate Sequences 
In accordance With degeneracy of genetic code, it is 
possible to substitute at least one base of the base sequence 
of a gene by another kind of base Without causing the amino 
acid sequence of the polypeptide produced from the gene to 
be changed. Hence, the DNA of the present invention may 
also have any base sequence that has been changed by 
substitution in accordance With degeneracy of genetic code. 
DNA Modi?cation 
The DNA is readily modi?ed by substitution, deletion or 
insertion of nucleotides, thereby resulting in novel DNA 
sequences encoding the polypeptide or its derivatives. These 
modi?ed sequences are used to produce mutant polypeptide 
and to directly express the polypeptide. Methods for satu 
rating a particular DNA sequence With random mutations 
and also for making speci?c site directed mutations are 
knoWn in the art; see eg Sambrook et al supra, Chapter 15. 
HybridiZable Variants 
The DNA molecule can comprise a nucleotide sequence 
as shoWn in Table 1, or can comprise a nucleotide sequence 
selected from the group consisting of a nucleotide sequence 
that hybridiZes to a DNA molecule encoding the amino acid 
sequence shoWn in Table 1 under salt and temperature 
conditions equivalent to 5><SSC and 42° C. Preferably, the 
DNA molecule is prehybridiZed in solution of 5><SSPE, 
5><denhardt’s and 0.5%SDS, 50% formamide, 20—100 pig/ml 
sonicated non-homologous DNA for 1 to 4 hours at 42° C., 
and then hybridiZed in the same solution but Without non 
homologous DNA and With denatured labeled DNA probe 
for overnight at 42° C. After hybridiZation, the ?lter is 
Washed tWice under less stringent conditions such as in 
2><SSPE, 0.1%SDS for 10 minutes at 42° C., a more 
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stringent condition is as follows: PrehybridiZation, hybrid 
iZation and less stringent Wash are the same as above, but a 
more stringent Wash condition is used such as: Wash in 
1><SSPE, 0.1%SDS at 60° C. for 10 to 30 minutes and then 
in 0.1><SSPE, 0.1%SDS at 60° C. for 10 minutes if neces 
sary. The hybridized DNA codes for a polypeptide that has 
one or more or all of the above-described physical and/or 
biological properties. The present invention also includes 
polypeptides coded for by these hybridiZable variants. See 
Chapters 11 and 12 of Sambrook et al, supra. 
Recombinant DNA Constructs 
Recombinant DNA constructs comprising one or more of 
the DNA or RNA sequences described herein and an addi 
tional DNA and/or RNA sequence are also included Within 
the scope of this invention. These recombinant DNA con 
structs have sequences Which do not occur in nature or exist 
in a form that does not occur in nature or exist in association 
With other materials that do not occur in nature. The DNA 
and/or RNA sequences described hereinabove are “operably 
linked” With other DNA and/or RNA sequences. DNA 
regions are operably linked When they are functionally 
related to each other. For example, DNA for a presequence 
or secretory leader is operably linked to DNA for a polypep 
tide if it is expressed as a preprotein Which participates in the 
secretion of the polypeptide; a promoter is operably linked 
to a coding sequence if it controls the transcription of the 
sequence; or a ribosome binding site is operably linked to a 
coding sequence if it is positioned so as to permit translation. 
Generally, operably linked means contiguous (or in close 
proximity to) and, in the case of secretory leaders, contigu 
ous and in reading phase. 
Vectors 
The invention is further directed to a replicable vector 
containing cDNA Which codes for the polypeptide and 
Which is capable of expressing the polypeptide. 
The present invention is also directed to a vector com 
prising a replicable vector and a DNA sequence correspond 
ing to the above described gene inserted into said vector. The 
vector may be an integrating or non-integrating vector and 
is conveniently a plasmid. 
Transformed Cells 
The invention further relates to a transformed cell or 
microorganism containing cDNA or a vector Which codes 
for the polypeptide or a fragment or variant thereof and 
Which is capable of expressing the polypeptide. 
Prokaryotic Host-Vector Systems 
A plethora of suitable microbial vectors are available. 
Generally, a microbial vector Will contain an origin of 
replication recogniZed by the intended host, a promoter 
Which Will function in the host and a phenotypic selection 
gene, for example, a gene encoding proteins conferring 
antibiotic resistance or supplying an auxotrophic require 
ment. 
Vectors must contain a promoter Which is recogniZed by 
the host organism. This is generally a promoter homologous 
to the intended host. Promoters often used in recombinant 
DNA construction include the [3-lactamase (penicillinase) 
and lactose promoter systems, a tryptophan (trp) promoter 
system and the tac promoter. While these are commonly 
used, other knoWn microbial promoters are suitable. Details 
concerning their nucleotide sequences have been published, 
enabling a skilled Worker to operably ligate them to DNA 
encoding the desired polypeptide in plasmid vectors and the 
DNA encoding the desired polypeptide. At the present time 
a preferred vector is pGEX vector With tac promotor, pRSET 
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vector With T7 promotor, or pET vector With T7 promotor. 
Other possible expression vectors are pTrc vector With trc 
promotor, pBAD vector With BAD promotor, pPROLar.A 
and pPROTet.E vector, and pRIT2T vector. 
Common prokaryotic host cells include bacteria such as 
E.c0li. 
Expression Systems Using Yeast Cells 
In addition to prokaryotes, eukaryotic microbes such as 
yeast cultures may be transformed With polypeptide encod 
ing vectors. Saccharomyces cerevisiae, or common baker’s 
yeast, is commonly used among loWer eukaryotic host 
microorganisms, although a number of other strains are 
commonly available. Yeast vectors generally Will contain an 
origin of replication from the 2 micron yeast plasmid or an 
autonomously replicating sequence (ARS), a promoter, a 
DNA sequence coding for the desired polypeptide, 
sequences for polyadenylation and transcription termination 
and a selection gene. 
Suitable promoting sequences in yeast vectors include the 
promoters for metallothionein, 3-phosphoglycerate kinase 
or other glycolytic enZymes. 
Other promoters, Which have the additional advantage of 
transcription controlled by groWth conditions, are the pro 
moter regions for alcohol dehydrogenase 2, isocytochrome 
C, acid phosphatase, degradative enZymes associated With 
nitrogen metabolism, and the aforementioned metallothion 
ein and glyceraldehyde-3-phosphate dehydrogenase, as Well 
as enZymes responsible for maltose and galactose utiliZa 
tion. In constructing suitable expression plasmids, the ter 
mination sequences associated With these genes are also 
ligated into the expression vector 3‘ of the polypeptide 
coding sequences to provide polyadenylation of the mRNA 
and termination. 
Expression Systems Using Vertebrate Cells 
Interest has been great in vertebrate cells, and propagation 
of vertebrate cells in culture (tissue culture) has become a 
routine procedure. Examples of useful mammalian host cell 
lines are VERO and HeLa cells, Chinese hamster ovary 
(CHO) cell lines, and W138, BHK, COS-7 and MDCK cell 
lines. Expression vectors for such cells ordinarily include (if 
necessary) an origin of replication, a promoter located 
upstream from the gene to be expressed, along With a 
ribosome binding site, RNA splice site (if intron-containing 
genomic DNA is used), a polyadenylation site, and a tran 
scriptional termination sequence. 
The transcriptional and translational control sequences in 
expression vectors to be used in transforming vertebrate 
cells are often provided by viral sources. For example, 
commonly used promoters are derived from polyoma, Aden 
ovirus 2, and most preferably Simian Virus 40 (SV40). The 
early and late promoters are particularly useful because both 
are obtained easily from the virus as a fragment Which also 
contains the SV40 viral origin of replication. Smaller or 
larger SV40 fragments may also be used, provided the 
approximately 250 bp sequence extending from the Hind III 
site toWard the BglI site located in the viral origin of 
replication is included. 
An origin of replication may be provided either by 
construction of the vector to include an exogenous origin, 
such as may be derived from SV40 or other viral (e.g., 
Polyoma, Adenovirus, VSV, or BPV) source, or may be 
provided by the host cell chromosomal replication mecha 
nism. If the vector is integrated into the host cell 
chromosome, the latter is often suf?cient. 
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Insect Cell Expression Systems 
Insect cell expression systems can be used With the 
present invention, as they are commonly described in 
Ausubel et al., Current Protocols in Molecular Biology, 
Green and Wiley, pub.(1994), Which is incorporated herein 
by reference in its entirety. 
Plant Cell Expression Systems 
Plant Vectors 
In plants, transformation vectors capable of introducing 
nucleic acid encoding deoxycytidyl (dCMP) transferase are 
easily designed, and generally contain one or more DNA 
coding sequences of interest under the transcriptional con 
trol of 5‘ and 3‘ regulatory sequences. Such vectors generally 
comprise, operatively linked in sequence in the 5‘ to 3‘ 
direction, a promoter sequence that directs the transcription 
of a doWnstream heterologous structural DNA in a plant; 
optionally a 5‘ non-translated leader sequence; a nucleotide 
sequence that encodes a protein of interest; and a 3‘ non 
translated region that encodes a polyadenylation signal 
Which functions in plant cells to cause the termination of 
transcription and the addition of polyadenylate nucleotides 
to the 3‘ end of the mRNA encoding said protein. Plant 
transformation vectors also generally contain a selectable 
marker. Typical 5‘-3‘ regulatory sequences include a tran 
scription initiation start site, a ribosome binding site, an 
RNA processing signal, a transcription termination site, 
and/or a polyadenylation signal. 
Plant Promoters 
Plant promoter sequences can be constitutive or inducible, 
environmentally- or developmentally-regulated, or cell- or 
tissue-speci?c. Often-used constitutive promoters include 
the CaMV 35S promoter, the enhanced CaMV 35S 
promoter, the FigWort Mosaic Virus (FMV) promoter, the 
mannopine synthase (mas) promoter, the nopaline synthase 
(nos) promoter, and the octopine synthase (ocs) promoter. 
Useful inducible promoters include heat-shock promoters, a 
nitrate-inducible promoter derived from the spinach nitrate 
reductase gene, hormone-inducible promoters, and light 
inducible promoters associated With the small subunit of 
RuBP carboxylase and LHCP gene families. Examples of 
useful tissue-speci?c, developmentally regulated promoters 
include the [3-conglycinin 7S promoter and seed-speci?c 
promoters. Plant functional promoters useful for preferential 
expression in seed plastics include those from plant storage 
protein genes and from genes involved in fatty acid biosyn 
thesis in oilseeds. Examples of such promoters include the 
5‘-regulatory regions from such genes as napin, phaseolin, 
Zein, soybean trypsin inhibitor, ACP, stearoyl-ACP 
desaturase, and oleosin. Seed-speci?c gene regulation is 
discussed in EP 0 255 378. Promoter hybrids can also be 
constructed to enhance transcriptional activity (Hoffman, 
US. Pat. No. 5,106,739), or to combine desired transcrip 
tional activity and tissue speci?city. 
Plant Transformation and Regeneration 
Avariety of different methods can be employed to intro 
duce such vectors into plant protoplasts, cells, callus tissue, 
leaf discs, meristems, etc., to generate transgenic plants, 
including Agrobacterium-mediated transformation, particle 
gun delivery, microinjection, electroporation, polyethylene 
glycol-mediated protoplast transformation, liposome 
mediated transformation, etc. In general, transgenic plants 
comprising cells containing and expressing DNAs encoding 
deoxycytidyl transferase can be produced by transforming 
plant cells With a DNA construct as described above via any 
of the foregoing methods; selecting plant cells that have 
been transformed on a selective medium; regenerating plant 
cells that have been transformed to produce differentiated 
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plants; and selecting a transformed plant Which expresses 
the enZyme-encoding nucleotide sequence. 
The encoding DNAs can be introduced either in a single 
transformation event (all necessary DNAs present on the 
same vector), a co-transformation event (all necessary 
DNAs present on separate vectors that are introduced into 
plants or plant cells simultaneously), or by independent 
transformation events (all necessary DNAs present on sepa 
rate vectors that are introduced into plants or plant cells 
independently). Traditional breeding methods can subse 
quently be used to incorporate the entire pathWay into a 
single plant. Speci?c methods for transforming a Wide 
variety of dicots and obtaining transgenic plants are Well 
documented in the literature. 
Successful transformation and plant regeneration have 
been achieved in the monocots as folloWs: asparagus 
(Asparagus o?icinalis; Bytebier et al, Proc. Natl. Acad. Sci. 
USA, 84:5345 (1987)); barley (Hordeum vulgarae; Wan and 
Lemaux, Plant Physiol., 104:37 (1994)); maiZe (Zea mays; 
Rhodes et al, Science, 240:204 (1988); Gordon-Kamm et al, 
Plant Cell, 2:603 (1990); Fromm et al, Bio/Technology, 
8:833 (1990); KoZiel et al, Bio/Technology, 11:194 (1993)); 
oats (Avena saliva; Somers et al, Bio/Technology, 10:1589 
(1992)); orchardgrass (Dactylic glomerata; Horn et al, Plant 
Cell Rep., 7:469 (1988)); rice (Oryza saliva, including 
indica and japonica varieties; Toriyama et al, Bio/ 
Technology, 6:10 (1988); Zhang et al, Plant Cell Rep., 7:379 
(1988); Luo and Wu, Plant Mol. Biol. Rep., 6:165 (1988); 
Zhang and Wu, Theor. Appl. Genet., 76:835 (1988); Chris 
tou et al, Bio/Technology, 9:957 (1991)); rye (Secale cere 
ale; De la Pena et al, Nature, 325:274 (1987)); sorghum 
(Sorghum bicolor; Cassas et al, Proc. Natl. Acad. Sci. USA; 
90:11212 (1993)); sugar cane (Saccharum spp.; BoWer and 
Birch, Plant J., 2:409 (1992)); tall fescue (Festuca aruna'i 
nacea; Wang et al, Bio/Technology, 10:691 (1992)); turf 
grass (Agrostis palustris; Zhong et al, Plant Cell Rep., 13:1 
(1993)); and Wheat (Triticum aestinum; Vasil et al, Bio/ 
Technology, 10:667 (1992); Weeks et al, Plant Physiol., 
102:1077 (1993); Becker et al, Plant J., 5:299 (1994)). 
Production of Transgenic Plants Comprising Genes for 
Deoxycytidyl Transferase 
Plant transformation vectors capable of delivering DNAs 
(genomic DNAs, plasmid DNAs, cDNAs, or synthetic 
DNAs) encoding deoxycytidyl transferase can be easily 
designed. Various strategies can be employed to introduce 
these encoding DNAs to produce transgenic plants capable 
of biosynthesiZing high levels of deoxycytidyl transferase 
including: 
1. Transforming individual plants With an encoding DNA 
of interest. TWo or more transgenic plants, each con 
taining one of these DNAs, can then be groWn and 
cross-pollinated so as to produce hybrid plants contain 
ing the tWo DNAS. The hybrid can then be crossed With 
the remaining transgenic plants in order to obtain a 
hybrid plant containing all DNAs of interest Within its 
genome. 
2. Sequentially transforming plants With plasmids con 
taining each of the encoding DNAs of interest, respec 
tively. 
3. Simultaneously cotransforming plants With plasmids 
containing each of the encoding DNAs, respectively. 
4. Transforming plants With a single plasmid containing 
tWo or more encoding DNAs of interest. 
5. Transforming plants by a combination of any of the 
foregoing techniques in order to obtain a plant that 
expresses a desired combination of encoding DNAs of 
interest. 
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Traditional breeding of transformed plants produced 
according to any one of the foregoing methods by successive 
rounds of crossing can then be carried out to incorporate all 
the desired encoding DNAs in a single homoZygous plant 
line (NaWrath et al, 1994; PCT International Publication WO 
93/02187). 
In methods 2 and 3, the use of vectors containing different 
selectable marker genes to facilitate selection of plants 
containing tWo or more different-encoding DNAs is advan 
tageous. Examples of useful selectable marker genes include 
those conferring resistance to kanamycin, hygromycin, 
sulphonamides, glyphosate, bialaphos, and phosphinothri 
cin. 
Stability of Transgene Expression 
As several overexpressed enZymes may be required to 
produce optimal levels of deoxycytidyl transferase, the 
phenomenon of co-suppression may in?uence transgene 
expression in transformed plants. Several strategies can be 
employed to avoid this potential problem. 
One commonly employed approach is to select and/or 
screen for transgenic plants that contain a single intact copy 
of the transgene or other encoding DNA. Agrobacterium 
mediated transformation technologies are preferred in this 
regard. 
Inclusion of nuclear scaffold or matrix attachment regions 
(MAR) ?anking a transgene has been shoWn to increase the 
level and reduce the variability associated With transgene 
expression in plants. Flanking a transgene or other encoding 
DNA With MAR elements may overcome problems associ 
ated With differential base composition betWeen such trans 
genes or encoding DNAs and integration sites, and/or the 
detrimental effects of sequences adjacent to transgene inte 
gration sites. 
The use of enhancers from tissue-speci?c or 
developmentally-regulated genes may ensure that expres 
sion of a linked transgene or other encoding DNA occurs in 
the appropriately regulated manner. 
The use of different combinations of promoters, plastid 
targeting sequences, and selectable markers for introduced 
transgenes or other encoding DNAs can avoid potential 
problems due to trans-inactivation in cases Where pyramid 
ing of different transgenes Within a single plant is desired. 
Finally, inactivation by co-suppression can be avoided by 
screening a number of independent transgenic plants to 
identify those that consistently overexpress particular intro 
duced encoding DNAs. Site-speci?c recombination in Which 
the endogenous copy of a gene is replaced by the same gene, 
but With altered expression characteristics, should obviate 
this problem. 
Any of the foregoing methods, alone or in combination, 
can be employed in order to insure the stability of transgene 
expression in transgenic plants of the present invention. 
ImmuniZation of Mice and Isolation of Polyclonal Anti 
bodies 
Antibodies to hREV1 are made using conventional 
methods, such as discussed in Ausubel et al. Current Pro 
tocols in Molecular Biology, Vol. 2, Supplement 18, Greene 
publishing and John Wiley & Sons (1994), Which is incor 
porated herein by reference in its entirety. An example of 
hoW the antibodies are made is as folloWs. Female 
B6SJLF1/J (Jackson Labs), approximately 8 Weeks of age, 
are immuniZed With hREV1 immunogen Which has been 
dissolved in PBS and emulsi?ed With an equal volume of 
complete Freund’s adjuvant. Using tWo groups of ?ve mice 
each, immuniZation is performed by intraperitoneal injection 
of 50.0 ug of hREV1 (With adjuvant) in a ?nal volume of 0.2 
ml PBS. At 4 Weeks and 8 Weeks post initial injection, each 
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mouse receives an identical quantity of hREV1 emulsi?ed 
With incomplete Freund’s adjuvant. Approximately 10 days 
after the second injection, serum sample are taken from each 
mouse via the retro-orbital sinus and are assayed for anti 
hREV1 antibody activity by competitive ELISA immunoas 
say determination. For those mice shoWing the presence of 
speci?c antibody in their serum, each is given a ?nal 
immuniZation of the identical hREV1 again in 0.1 ml of PBS 
injected into the tail vein 3 days prior to sacri?ce of the 
animal. 
The competitive ELISA immunoassay also is used to 
determine the presence of speci?c antibodies against hREV1 
in mouse sera (and subsequently to identify speci?c 
hybridomas); these assays are modi?cations of methods 
previously described in the art (Haugen et al., Proc. Natl. 
Acad. Sci. U.S.A. 78:4124—4127 (1981); Groopman et al., 
Cancer Res. 42:3120—3124 (1982)). Brie?y summariZing 
the procedure, hREV1 is dissolved in PBS at a concentration 
of 2.0 pig/ml and 50 ul of this ?uid mixture is added to each 
Well of a polyvinyl microtiter plate and alloWed to incubate 
for 2—4 hours at ambient temperature. Other Wells in the 
microtiter plate receive 50 ul of gelatin in PBS at a concen 
tration of 2 ug/ml and serve as controls. The ?uid in each 
Well is then aspirated and each Well is Washed 3 times With 
PBS With 0.05% (vol/vol) TWEEN 20. Subsequently, each 
Well receives a PBS solution containing 0.2% gelatin and the 
plates are alloWed to incubate for an additional hour at 
ambient temperature. This procedure is designed to limit 
non-speci?c binding of antibodies. The plates are then 
Washed in PBS With 0.05% TWEEN 20 and 50 ul aliquots 
of diluted mouse serum samples (or hybridoma medium) 
plus appropriate competitor are added to each Well. To titer 
the mouse sera, dilutions in PBS With 0.05 % TWEEN 20 are 
prepared over a range from 1:100—1:51,200 in continuing 
tWo-fold dilutions. The microtiter plates are then incubated 
for 90 minutes at 37° C., after Which they are thoroughly 
Washed With PBS+0.05% TWEEN 20. Speci?c antibodies 
that become bound to the surface of each Well are detected 
by adding 50 ul of a 1:1000 dilution of goat anti-mouse 
IgG+IgM antibody coupled to alkaline phosphatase to each 
Well folloWed by incubation of 90 minutes at 37° C. The 
Wells in each plate are then reWashed With PBS With 
TWEEN 20 plus a ?nal Wash With tap Water. 100 pl per Well 
of 1.0 mg/ml p-nitrophenyl phosphate solution (Sigma) 
prepared in 0.1M diethanolamine buffer, pH 9.8 then is 
added and alloWed to react for 30 min. Quantitative mea 
surement of the p-nitrophenol reaction product is performed 
by measuring the absorbance of the assay Well at 405 
nanometers using a microtiter plate reader (Dynatech Labs). 
The isotypes of the monoclonal antibodies (that is the 
determination and identi?cation of different antibody heavy 
chain class) are determined in a non-competitive ELISA 
methodology using a commercially purchased kit for mouse 
immunoglobulin subtype identi?cation (Boeringer 
Mannheim Company). 
Preparation of Hybridomas and Isolation of Monoclonal 
Antibody Producing Cells 
Hybridomas and monoclonal antibodies to hREV1 are 
prepared using conventional methods, such as discussed in 
Ausubel et al. Current Protocols in Molecular Biology, Vol. 
2, Supplement 18, Green Publishing and John Wiley & Sons 
(1994), Which is incorporated herein by reference in its 
entirety. An example of hoW the hybridomas and mono 
clonal antibodies are made is as folloWs. The female 
B6SJLF1/J mice previously immuniZed With hREV1 in 
complete Freund’s adjuvant are tested for production of 
signi?cant anti-hREV1 serum titers using the competitive 
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ELISA methodology as described above. Those mice shoW 
ing high titers are sacri?ced and hybridomas prepared fol 
lowing the procedures previously described in Marshak 
Rothstein et al., J. Immun, 122:2491—2497 (1979). The 
myeloma cell line used for cell fusion are P3-X63/Ag8.653 
cells Which Were maintained in Dulbecco’s Modi?ed Eagles 
medium (hereinafter “DME” medium) supplemented With 
20% (volume/volume) fetal calf serum, 2 mM L-Glutamine, 
10 units/ml penicillin, 100 pig/ml streptomycin, and non 
essential amino acids (Gibco). The mice are sacri?ced and 
spleen cell suspensions prepared using Hanks’ balance salt 
solution buffered With 0.01M phosphate, pH 7.2 (hereinafter 
“HPBS”). 
The spleen cells from these mice are fused With P3-X63/ 
Ag8.653 myeloma cells using a modi?cation of the Gefter et 
al. procedure (Somatic Cell Genet. 3:321 (1977)). Unless 
stated otherWise, all centrifugations are preformed at 700 
times gravity for 5 minutes at room temperature. Preferably, 
5><106 P3-X63/Ag8.653 myeloma cells and 2.5><107 immune 
spleen cells are combined in a round bottom plastic tube, 
centrifuged, resuspended in 10 ml of serum free DME 
medium and centrifuged again. The supernatant is carefully 
discarded and the centrifuge tube tapped sharply to disperse 
the residual cell pellet. The cells are then exposed to 0.5 ml 
of a 30% (volume/volume) solution of polyethylene glycol 
1000 (Baker Chemical Company) in serum free DME for 6 
minutes. During this 6 minute period, the cell suspension is 
gently centrifuged (150><gravity for 3 minutes). 4.0 ml of 
serum free DME is then added to the cell pellet and the cells 
again resuspended by tapping the tube. The contents of the 
tube are transferred to 100><17 mm Petri dishes and cultured 
in DME medium containing 20% fetal calf serum for 1 day. 
The cells are then centrifuged again and resuspended in 
groWth medium containing hypoxanthine, aminopterin and 
thymidine (hereinafter “HAT medium”). 0.1 ml aliquots of 
the cells are then distributed into the Wells of ?at bottom 
microtiter dishes, each aliquot containing approximately 105 
P3-X63/Ag8.653 cells. After one Week’s incubation, 0.05 ml 
of groWth medium containing only hypoxanthine and thy 
midine (hereinafter “HT medium”) is added to each Well. 
Cultures are screened for speci?c anti-hREV1 antibody 
activity tWo Weeks post fusion using the competitive ELISA 
immunoassay technique described earlier. 
Hybridomas secreting monoclonal antibodies of high 
af?nity speci?c for hREV1 are groWn as ascites tumor cells 
in Scid mice Which has been previously injected With 0.5 ml 
pristane (Aldrich). The hybridomas groWing Within the mice 
produce large quantities of speci?c monoclonal antibodies 
Which are harvested and collected as ascites ?uid from each 
mouse before it dies. The collected ?uid from these animals 
is pooled and either used directly in the immunoassays or 
further puri?ed by saturated ammonium sulfate precipitation 
and dialysed against PBS. Gross pathological examination 
shoWs that all mice die as a result of Widespread tumor 
invasion—that is groWth of the injected hybridoma cells. 
Utility 
The gene or DNA of the present invention and the 
polypeptide Which is coded by the DNA of the present 
invention have various potential uses. 
1. It is possible that the polypeptide of the present 
invention is useful as a deoxycytidyl transferase. Thus, 
if the polypeptide of the present invention is introduced 
into or contacted With a cell, it Will cause a speci?c 
mutagenic bypass opposite an abasic site. 
2. A drug might exist or might be developed Which 
speci?cally enhances or inhibits the function of this 
polypeptide. Knowledge of the precise sequence bound 
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by the polypeptide provides an obvious approach to 
targeted drug therapy. 
3. It is also possible that an anti-sense sequence Which 
binds to single stranded RNA corresponding to the gene 
of the present invention could be made Whereby the 
anti-sense sequence Would bind to single stranded RNA 
to prevent expression of the polypeptide. 
Therapeutic Uses 
In the practice of the therapeutic methods of the present 
invention, an effective amount of the active compound, 
including derivatives or salts thereof, or a pharmaceutical 
composition containing the same, as described beloW, is 
administered via any of the usual and acceptable methods 
knoWn in the art, either singly or in combination With 
another compound or compounds of the present invention or 
other pharmaceutical agents such as immunosuppressants, 
antihistamines, corticosteroids, and the like. These com 
pounds or compositions can thus be administered orally, 
sublingually, topically (e.g., on the skin or in the eyes), by 
inhalation or by suppository, parenterally (e.g., 
intramuscularly, intravenously, subcutaneously or 
intradermally), or by inhalation, and in the form of either 
solid or liquid dosage including tablets, suspensions, and 
aerosols, as is discussed in more detail beloW. The admin 
istration can be conducted in single unit dosage form With 
continuous therapy or in single dose therapy ad libitum. A 
unit dose is de?ned as 1 to 3000 mg for a human patient. 
Useful pharmaceutical carriers for the preparation of the 
pharmaceutical compositions hereof can be solids, liquids or 
mixtures thereof; thus, the compositions can take the form of 
tablets, pills, capsules, poWders, enterically coated or other 
protected formulations (such as binding on ion exchange 
resins or other carriers, or packaging in lipid or lipoprotein 
vesicles or adding additional terminal amino acids), sus 
tained release formulations, erodible formulations, implant 
able devices or components thereof, microsphere 
formulations, solutions (e.g., ophthalmic drops), 
suspensions, elixirs, aerosols, and the like. 
Water, saline, aqueous dextrose, and glycols are preferred 
liquid carriers, particularly (When isotonic) for injectable 
solutions. The carrier can be selected from various oils 
including those of petroleum, animal, vegetable or synthetic 
origin, for example, peanut oil, soybean oil, mineral oil, 
sesame oil, and the like. Suitable pharmaceutical excipients 
include starch, cellulose, talc, glucose, lactose, sucrose, 
gelatin, malt, rice, ?our, chalk, silica gel, magnesium 
stearate, sodium stearate, glycerol monostearate, sodium 
chloride, dried skim milk, glycerol, propylene glycol, Water, 
ethanol, and the like. The compositions may be subjected to 
conventional pharmaceutical expedients such as steriliZation 
and may contain conventional pharmaceutical additives 
such as preservatives, stabiliZing agents, Wetting or emulsi 
fying agents, salts for adjusting osmotic pressure, buffers, 
and the like. Suitable pharmaceutical carriers and their 
formulations are described in Martin, “Remington’s Phar 
maceutical Sciences”, 15th Ed.; Mack Publishing Co., Eas 
ton (1975); see, e.g., pp. 1405—1412 and pp. 1461—1487. 
Such compositions Will, in general, contain an effective 
amount of the active compound together With a suitable 
amount of carrier so as to prepare the proper dosage form for 
proper administration to the host. 
In one preferred embodiment, the therapeutic methods of 
the present invention are practiced When the relief of symp 
toms is speci?cally required or perhaps imminent; in another 
preferred embodiment, the method hereof is effectively 
practiced as continuous or prophylactic treatment. 
In the practice of the therapeutic methods of the invention, 
the particular dosage of pharmaceutical composition to be 
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administered to the subject Will depend on a variety of 
considerations including the nature of the disease, the sever 
ity thereof, the schedule of administration, the age and 
physical characteristics of the subject, and so forth. Proper 
dosages may be established using clinical approaches famil 
iar to the medicinal arts. It is presently believed that dosages 
in the range of 0.1 to 100 mg of compound per kilogram of 
subject body Weight Will be useful, and a range of 1 to 100 
mg per kg generally preferred, Where administration is by 
injection or ingestion. Topical dosages may utiliZe formu 
lations containing generally as loW as 0.1 mg of compound 
per ml of liquid carrier or excipient, With multiple daily 
applications being appropriate. 
The invention being thus described, it is obvious that the 
same can be varied in many Ways. Such variations are not to 
be regarded as a departure from the spirit and scope of the 
present invention, and all such modi?cations as Would be 
obvious to one skilled in the art are intended to be included 
Within the scope of the folloWing claims. 
EXAMPLES 
Materials and Methods 
Materials 
Human bone marroW and leukocyte cDNA libraries in 
)tgt11 Were purchased from Clontech Laboratories. Ahuman 
T cell cDNA library in the ZAP Express vector and a human 
placenta genomic DNA library Were purchased from Strat 
agene. E. coli uracil-DNA glycosylase Was obtained from 
NeW England BioLabs. The vector pUC19M1 Was con 
structed by Deepak Rajpal by adding BglII, EcoRV, NcoI, 
and XhoI sites into the multiple cloning region of plasmid 
pUC19 immediately after the HindIII site. The plasmid 
vector PCR-Script Was obtained from Stratagene. The E. 
coli strains XL1-Blue MRF‘ and XLOLR Were purchased 
from Stratagene. The yeast strain CL1265rev1A (MATU. 
rev1A arg4-17 leu2-3,112 his3-A1 trp ura3-52) Was derived 
from CL1265-7C (1) by deleting the REV1 gene. 
Isolation of Human REV1 cDNA 
Based on a human EST sequence (GenBank accession 
number AA029147), a 59-mer oligonucleotide (probe I), 
CATGGTACGAAAGCCTGGGGTCCTGTA 
GAAACTGCAAAATTTGGAGGCCATGGAATTTG 
(SEQ ID N011), Was synthesiZed. After labeling With 32P at 
its 5‘ end by T4 polynucleotide kinase, the probe Was used 
to screen human bone marroW and leukocyte cDNA libraries 
by plaque DNA hybridiZation (23). Seventeen positive 
clones Were isolated from approximately 1.6 million inde 
pendent clones. Each insert cDNA Was either directly sub 
cloned into the EcoRI site of pUC19 plasmid vector or 
ampli?ed by PCR prior to plasmid subcloning using the )» 
phage-derived primers, CGGCAGTACAATGGATTTCCTT 
(SEQ ID N012) and CATCGCCATCTGCTGCAC (SEQ ID 
N013). These cDNA inserts Were sequenced by the standard 
dideoxynucleotide chain termination method on both 
strands. The overlapping cDNA sequences yielded a partial 
cDNA sequence of 4.2 kb. Based on the 5‘ region of this 
sequence, tWo 59-mer oligonucleotides, CATTAGTTTTCT 
CAATCTCAGCGGAAGATCTGTGTATC 
CATTAACATAGATGGCAACTC (SEQ ID N014) (probes 
II) and CCACCCCATGTTTTCCAGCCAT 
CATTTTCAGCTCGCTTCCTCCATCCAC 
CTCGCCTCAT (SEQ ID N015) (probe III), Were synthe 
siZed and used to screen a human T cell cDNA library. 
Approximately 40 cDNA clones Were isolated and their 
insert sequences determined. Additional 5‘ sequence of the 
human REV1 cDNA Was obtained from some clones. Com 
bining the 5‘ and 3‘ sequences of various cDNA clones, the 
complete sequence of a 4,255-bp human REV1 cDNA Was 
generated. 
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Construction of a Full-length Human REV1 cDNA 
The insert cDNA from tWo )tgt11 clones With overlapping 
partial human REV1 cDNA sequences Were excised from 
the phage DNA With SalI restriction endonuclease and 
subcloned into the plasmid vector pUC19M1. The resulting 
plasmids, pWL269 and pWL270, contain the 3‘ half and the 
5‘ half of the human REV1 cDNA, respectively. The full 
length human REV1 cDNA Was constructed by ligating a 1.7 
kb XbaI-SphI fragment from pWL270 and a 2.7 kb Sphl 
SacI fragment from pWL269 into the SacI-XbaI sites of the 
plasmid vector pUC19. The resulting recombinant plasmid, 
pWL296, contained the full-length human REV1 cDNA. 
Isolation of Human REV1 Genomic Clones 
A human REV1 clone from the human T cell cDNA 
library Was excised in vivo from the ZAP Express vector in 
E. coli XL1-Blue MRF‘ cells infected With a M13 helper 
phage. The resulting packaged phagemid particles Were used 
to infect E. coli XLOLR cells to convert the phagemid into 
a double-stranded plasmid containing the human REV1 
cDNA. The recovered plasmid Was then digested With 
EcoRI restriction endonuclease, releasing the 0.8 kb human 
REV1 cDNA insert (corresponding to the human REV1 
cDNA position —178 to +646) from the plasmid vector. After 
isolating it from an agarose gel, this cDNA fragment Was 
used as the template to prepare 32P-labeled DNA probes by 
randomly primed DNA synthesis. Approximately 2 million 
clones from a human placenta genomic DNA library Were 
screened With the human REV1 probes. TWo clones Were 
isolated. The DNA inserts of approximately 20 kb each Were 
subcloned into the NotI site of PCR-Script vector and 
partially sequenced. 
Northern Blot Analysis of the Human REV1 mRNA 
A 59-mer oligonucleotide probe, corresponding to the 
human REV1 cDNAposition —126 to —184, Was synthesized 
and labeled With 32P at its 5‘ end by T4 polynucleotide 
kinase. A human mRNA blot (Invitrogen) Was hybridiZed 
With the probe in a buffer containing 50% formamide, 0.25 
M NaCl, 0.25 M sodium phosphate, pH 7.2, 1 mM EDTA, 
and 5% SDS at 42° C. for 18 h. The blot Was Washed With 
15 mM NaCl, 1 mM sodium phosphate, pH7.4, and 0.1 mM 
EDTA at 60° C. for 1 h. The hybridiZed human REV1 
mRNA Was visualiZed by autoradiography at —80° C. With 
an intensifying screen. 
Detection of the Human REV1 Expression 
Expression of the REV1 gene in various human tissues 
Was detected by RT-PCR. Poly(A) mRNA samples Were 
isolated from various human tissues and used for ?rst strand 
cDNA synthesis by reverse transcriptase. These cDNA 
samples Were then normaliZed against glyceraldehyde-3 
phosphate dehydrogenase cDNA. Such human multiple tis 
sue cDNA panels Were purchased from Clontech Laborato 
ries and used for PCR. TWo PCR primers, 
CCCAGGAGGAGGATAAGGCTG (SEQ ID N016) and 
GTCTTTGTAGGGTATTGACAAACTCAGTC (SEQ ID 
N017), Were used to amplify a 360 bp region of the human 
REV1 cDNA. PCR reactions (20 pl) contained 0.4 ng 
cDNA, 5 pmol each of the primers, 2 mM MgCl2, 20 mM 
Tris-HCl, pH8.0, 50 mM KCl, 200 pM each of dATP, dCTP, 
dGTP, and dTTP, and 1 unit of Taq DNA polymerase. After 
heating at 94° C. for 30 sec, 35 cycles of ampli?cation Were 
performed according to the folloWing conditions: 20 sec 
denaturation at 94° C., 30 sec annealing at 60° C., and 45 sec 
extension at 68° C. Reaction products Were separated by 
electrophoresis on a 1% agarose gel containing 0.5 pig/ml 
ethidium bromide. 
Puri?cation of the Human REV1 Protein 
The 5‘ 2.3 kb open reading frame of the human REV1 
cDNA Was ampli?ed from pWL296 by PCR, generating a 
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DNA fragment ?anked by XbaI (added by the 5‘ PCR 
primer) and HindIII sites. This DNA fragment Was cloned 
into the XbaI-HindIII sites of the yeast expression vector 
pEGLh6 (24). At its HindIII site, a 2 kb HindIII DNA 
fragment containing the missing 3‘ end of the human REV1 
Was then transferred from pWL296. The resulting plasmid 
pEGLh6-hREV1 codes for the full-length human REV1 
protein tagged With 6 histidine residues at its N-terminus. 
Ayeast rev1 delta deletion mutant strain Was transformed 
With pEGLh6-hREV1 for regulated human REV1 expres 
sion under the control of the GAL1/10 promoter. Yeast cells 
containing pEGLh6-hREV1 Were groWn in minimum 
medium containing 2% sucrose to late logarithmic phase. 
Expression of the human REV1 Was induced by diluting the 
culture 10-fold in 16 LofYPG (2% Bacto-peptone, 1% yeast 
extract, and 2% galactose) medium supplemented With 
sucrose to a ?nal concentration of 0.5% and groWth for 16 
h at 30° C. Cells Were collected by centrifugation at 6,000><g 
for 10 min at 4° C. and Washed in Water. After resuspending 
in an extraction buffer containing 50 mM Tris-HCl, pH7.5, 
600 mM KCl, 10% sucrose, 5 mM [3-mercaptoethanol, and 
protease inhibitors (25), cells Were homogeniZed by Zirco 
nium beads in a Bead-beater (BioSpec Products) for 15 
pulses of 30 sec each. The clari?ed extract (~100 ml) Was 
loaded onto a Ni2+-Sepharose column (10 ml) (Amersham 
Pharmacia Biotech), folloWed by Washing the column With 
100 ml of Ni buffer A(20 mM potassium phosphate, pH7.2, 
0.5 M NaCl, 20 mM imidaZole, 10% glycerol, 5 mM 
[3-mercaptoethanol and protease inhibitors). Bound proteins 
Were eluted With a linear gradient of 20 mM to 135 mM 
imidaZole (100 ml). The REV1 protein fractions Were iden 
ti?ed by Western blots using a monoclonal anti-His antibody 
(Qiagene) and pooled. NaCl in the human REV1 sample Was 
replaced With 50 mM KCl by passing the sample through a 
G-25 Sephadex column. Some protein precipitates Were 
formed, Which contained a signi?cant amount of the human 
REV1 protein. The protein precipitates Were recovered by 
centrifugation at 20,000><g for 10 min at 4° C. and dissolved 
in a buffer containing 20 mM potassium phosphate, pH7.2, 
1 M KCl, 10% glycerol, and 5 mM [3-mercaptoethanol. This 
sample containing partially puri?ed hREV1 Was used for 
some activity assays. To further purify the human REV1 
protein, the soluble fraction from the G-25 Sephadex col 
umn Was loaded onto a FPLC Mono S HR 5/5 column 
(Amersham Pharmacia Biotech) that had been equilibrated 
in P buffer (20 mM KH2PO4, pH7.4, 1 mM EDTA, 5 mM 
B-mercaptoethanol, 10% glycerol, and protease inhibitors) 
containing 50 mM KCl. The column Was eluted With a linear 
KCl gradient from 50 mM to 500 mM in P buffer. The 
human REV1 eluted at ~190 mM KCl. The KCl concentra 
tion in the combined Mono S fractions Were reduced to 50 
mM by gel ?ltration through a G-25 Sephadex column, and 
subsequently loaded onto a FPLC Mono Q HR 5/5 column 
(Amersham Pharmacia Biotech). Column equilibration and 
elution conditions Were as in the Mono S chromatography. 
The most pure human REV1 eluted at ~320 mM KCl. 
Deoxycytidyl Transferase Assay 
Deoxycytidyl transferase assays Were performed essen 
tially as described by Nelson et al. (15). The reaction 
mixture (10 pl) contained 25 mM potassium phosphate 
buffer, pH 7.4, 5 mM MgCl2, 0.1 mg/ml BSA, 10% glycerol, 
5 mM dithiothreitol, 100 pM dNTP (dATP, dCTP, dGTP, 
dTTP, or all four), 20 nM of 5‘ end 32P-labeled oligonucle 
otide primer annealed to an oligonucleotide template as 
indicated, and protein sample. After incubation at 30° C. for 
30 min, reactions Were terminated With 7 pl of stop solution 
(20 mM EDTA, 95% formamide, 0.05% bromophenol blue, 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
22 
and 0.05% xylene cyanol). The reaction products Were 
resolved on a 12% polyacrylamide gel containing 8 M urea 
and visualiZed by autoradiography. To obtain DNA substrate 
containing an abasic site, the uracil-containing substrate (10 
pmol) Was treated With 2 units of E. coli uracil-DNA 
glycosylase at 37° C. for 60 min. Under this condition, the 
site-speci?c uracil residue Was converted to an AP site in the 
template. 
Results 
Cloning of the Human REV1 cDNA 
Using the yeast Rev1 protein sequence, the non-redundant 
GenBank CDS database Was searched for its homologues. A 
C. elegans hypothetical protein (ZK675.2) Was identi?ed. 
Alignment of 710 amino acid residues shoWed 27% identity 
and 44% similarity to the yeast Rev1. Thus, this C. elegans 
protein is a homologue of the yeast Rev1. Using the C. 
elegans REV1 protein sequence, the GenBank EST 
(expressed sequence tag) database Was subsequently 
searched a human EST clone (GenBank accession number 
AA029147) Was identi?ed. Based on this clone, the EST 
database Was searched again and tWo related EST clones 
(GenBank accession numbers AA393888 and T08134) Were 
identi?ed. Combining the three EST sequences, a partial 3‘ 
cDNA sequence of the putative human REV1 gene Was 
obtained. 
To isolate the full-length human REV1 cDNA, a 59-mer 
oligonucleotide probe Was synthesiZed and three human 
cDNA libraries Were screened. As a result, an additional 5‘ 
sequence of the putative human REV1 gene Was obtained. 
Subsequently, tWo additional 5 9-mer oligonucleotide probes 
Were synthesiZed and used to screen the human cDNA 
libraries. Forty cDNA clones Were isolated, the largest of 
Which contained an insert of 4 kb. The 5‘ sequence of the 
putative human REV1 gene Was generated after sequencing. 
Finally, a cDNA clone containing both the 5‘ and the 3‘ 
sequences Was reconstructed from partial cDNA clones 
(GeneBank accession number AF 151538). This cDNA 
(4,255 bp) codes for a protein of 1,251 amino acid residues 
With a calculated molecular Weight of 138,248 Da and p1 of 
8.76. Upon searching the GenBank With Applicants’ protein 
sequence, the yeast Rev1 Was identi?ed as its homologue 
(PN=5><e_3°). Hence, Applicants’ cDNA clone codes for a 
human homologue of the yeast mutagenesis protein Rev1. 
Accordingly, this cDNA and its gene is referred to as the 
human REV1. 
The sequence context of the putative ATG start codon 
(CCACCATGA) in Applicants’ human REV1 clone matches 
Well With the KoZak consensus sequence (CCACCATGG), 
Which is commonly found surrounding the mammalian ATG 
initiator codon (26). HoWever, the 5‘ untranslated region of 
this human REV1 cDNA does not contain an in-frame 
termination codon. Furthermore, tWo cDNA clones con 
tained an intron-like sequence 5‘ upstream of the position 
—10, in Which the sequence context at the junction closely 
resembles the consensus sequence of the 3‘ splicing site. 
These observations raised the question Whether the full 
length human REV1 Was indeed isolated. To ansWer this 
question, the siZe of the human REV1 mRNA Was ?rst 
determined by a Northern blot analysis. As shoWn in FIG. 1, 
the human REV1 mRNA Was estimated to be 4.5 kb. This is 
in good agreement With the siZe of Applicants’ cDNA clone 
(4.3 kb). Secondly, a human genomic library Was screened 
using the human REV1 cDNA as the probe. TWo overlap 
ping genomic clones Were isolated. Sequencing these clones 
con?rmed the presence of the 5‘ splicing site and revealed 
multiple termination codons upstream of the cDNA 
sequence (GenBank accession number AF 153594). These 
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results show that Applicants have isolated the full-length 
cDNA of the human REV1. Additionally, the results indicate 
that the ?rst exon of the human REV1 gene is non-coding. 
In the human REV1 cDNA, an out-of-frame ATG codon 
is located 32 nucleotides upstream of the initiator codon, 
Which could potentially direct the synthesis of a polypeptide 
of 12 amino acids. Translation from this ?rst ATG codon 
Would lead to an aborted human REV1 protein synthesis. 
Thus, the translational ef?ciency of the human REV1 mRNA 
may be reduced. 
Conservation of REV1 Protein Sequences from Yeast to 
Humans 
Sequence alignment betWeen the yeast and the human 
REV1 proteins revealed signi?cant homology (FIG. 2). Four 
conserved regions Were identi?ed With amino acid sequence 
identities of 21—35% and similarities of 43—59% (FIG. 2). 
After the human REV1 cDNA Was cloned, the A. thaliana 
and the S. pombe REV1 homologues (GenBank accession 
numbers AC002342 and AL035548, respectively) Were also 
identi?ed from the genomic sequencing projects. Again, 
protein sequence conservation Was found among these pro 
teins (FIG. 3). Comparison of various REV1 proteins 
revealed a BRCT (BRCA1 C-terminus) domain at their 
N-terminal regions and ?ve sequence motifs (FIG. 3). 
Chromosomal Localization of the Human REV1 Gene 
Using the human REV1 cDNA as the probe, tWo human 
REV1 genomic clones Were isolated from a library. One 
clone contained a sequence tagged site (STS), EST164698 
(GenBank accession number G25709), upstream from the 5‘ 
end of the human REV1 gene. The distance betWeen this 
STS and the 5‘ sequence of the human REV1 cDNA Was 
estimated to be 20 kb by PCR using either the genomic clone 
or the total genomic DNA isolated from human placenta 
(data not shoWn). The location of this STS Was assigned to 
512.6 cR from the top of Chromosome 2 linkage group by 
Radiation Hybrid Mapping of marker SGC33758 by the 
Whitehead Institute/MIT Center for Genome Research. On 
GeneMap’98, it Was further mapped to physical position: 
355.80 cR3000 (P>3.00) betWeen reference intervals 
D2S113—2S176 (115.3—120.8 cM). These markers are local 
iZed betWeen 2q11.1 and 2q11.2 on the cytogenetic ideo 
gram. Therefore, We conclude that the human REV1 gene is 
located betWeen 2q11.1 and 2q11.2. 
Expression of the REV1 Gene in Human Tissues 
In yeast, the Rev1-involved mutagenesis pathWay is a 
major mechanism for generating mutations after DNA dam 
age. HoWever, it is not knoWn Whether this pathWay func 
tions in various human tissues. Thus, the expression of the 
REV1 gene Was examined as an indication of the importance 
of this putative mutagenesis pathWay in various human 
tissues. As shoWn in FIG. 4, the human REV1 expression 
Was detected by RT-PCR in all of the 16 tissues examined. 
Hence, We conclude that the REV1 gene is ubiquitously 
expressed in humans. 
The Human REV1 Protein is a dCMP Transferase 
The yeast Rev1 protein possesses a deoxycytidyl trans 
ferase activity, Which transfers a dCMP residue to the 3‘ end 
of a DNA primer opposite a template G or an AP site (15). 
To determine Whether the human REV1 protein is a dCMP 
transferase, the protein Was ?rst partially puri?ed and then 
the dCMP transferase activity Was assayed. To facilitate 
detection and puri?cation of the human REV1, the protein 
Was tagged With six histidine residues at its N-terminus, and 
Was expressed in yeast rev1 deletion mutant cells. The 
tagged human REV1 Was puri?ed by af?nity chromatogra 
phy on a nickel-Sepharose column. As a control, rev1 
deletion mutant extracts Were used for identical puri?cation. 
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Using a primed 40-mer DNA template (FIG. 5A), the 
transferase activity of the partially puri?ed human REV1 
Was assayed. As shoWn in FIG. 5B (lane 10), a transferase 
activity Was detected that extended the 32P-labeled primer 
by tWo nucleotides opposite the tWo template G residues. In 
contrast, the control sample Without the human REV1 did 
not contain any detectable transferase activity (FIG. 5B, lane 
9), indicating that the transferase activity is speci?c to the 
human REV1 protein. To identify the nucleotides transferred 
opposite the template G residues, the transferase assays Were 
performed With dATP, dCTP, dGTP, or dTTP individually, 
rather than all four dNTPs together. Only dCTP supported 
the transferase activity (FIG. 5B, lane 4). Again, the trans 
ferase activity Was not detected With the control sample 
Without the human REV1 protein (FIG. 5B, lanes 1, 3, 5, and 
7). The transferase activity Was not observed opposite a 
template A, C, or T (data not shoWn). Hence, the human 
REV1 protein is a dCMP transferase, Which transfers dCMP 
opposite a template G. Supporting this conclusion, the 
transferase activity co-puri?ed With the human REV1 as 
revealed by Western blots during nickel-Sepharose column 
chromatography (data not shoWn). In the control puri?cation 
from rev1 deletion mutant extracts, none of the fractions 
contained the transferase activity (data not shoWn). 
To examine Whether the transferase activity of the human 
REV1 functions opposite a template AP site, a site-speci?c 
uracil-containing template Was prepared (FIG. 6A). Treat 
ment With uracil-DNA glycosylase completely converted the 
uracil-containing templates into AP site-containing 
templates, as revealed by the AP site cleavage With the E. 
coli endonuclease III (FIG. 6B, lane 2). Transferase activity 
of the human REV1 Was detected opposite the template AP 
site (FIG. 6C, lane 9). A template U also supported the 
human REV1 transferase activity (FIG. 6C, lane 10). This is 
also observed With the yeast Rev1 protein (15). HoWever, 
unlike the yeast protein, Which utiliZes the template AP site 
much more ef?ciently than the template U for its transferase 
activity (15), the human REV1 uses both the template AP 
site and uracil efficiently (FIG. 6C, compare lanes 9 and 10). 
To identify the nucleotides transferred opposite the template 
AP site or uracil, the transferase assays Were performed With 
only one deoxynucleoside triphosphate, dATP, dCTP, dGTP, 
or dTTP. As shoWn in FIG. 6C (lanes 3 and 4), only dCTP 
supported the human REV1 transferase activity opposite the 
template AP site or uracil. These results shoW that the human 
REV1 protein is a template-dependent dCMP transferase 
that is active opposite a template G, U, or AP site. 
The yeast REV1 gene had been deleted from the host cells 
used for the human REV1 expression and puri?cation. Thus, 
the yeast Rev1 could not have contaminated the human 
REV1 protein preparations. Nevertheless, to provide further 
support to the conclusion that the human REV1 is a dCMP 
transferase, the protein Was puri?ed to apparent homogene 
ity (FIGS. 7A and 8B). Again, a transferase activity opposite 
an AP site Was observed With the pure human REV1 
preparation (FIG. 7C). Additionally, When the transferase 
assay Was performed opposite a template G using the pure 
human REV1 protein, the dCMP transferase activity Was 
detected (data not shoWn). These results shoW that the 
observed dCMP transferase activity is associated With the 
human REV1 protein. 
Whereas particular embodiments of this invention have 
been described above for purposes of illustration, it Will be 
evident to those persons skilled in the art that numerous 
variations of the details of the present invention may be 
made Without departing from the invention as de?ned in the 
appended claims. 


















